PCOS Renamed to PMOS
A long-standing women’s health condition known for decades as polycystic ovary syndrome (PCOS) has officially been renamed polyendocrine metabolic ovarian syndrome (PMOS), marking one of the most significant reclassifications in reproductive and metabolic medicine in years. The change, announced in a peer-reviewed paper published in The Lancet and presented at the European Congress of Endocrinology, follows more than a decade of global research, patient input, and clinical review involving tens of thousands of participants.
Why the Name is changing
Medical experts say the term PCOS has been misleading for years, implying the condition is primarily about ovarian cysts when that is not necessarily the case. The new name, PMOS, is intended to reflect what researchers now describe as a whole-body endocrine and metabolic disorder rather than a narrowly reproductive condition. “The term PCOS is inaccurate, implying pathological ovarian cysts, obscuring diverse endocrine and metabolic features, and contributing to delayed diagnosis, fragmented care, and stigma,” researchers wrote in the Lancet consensus paper. Under the updated framework, PMOS highlights disruptions across multiple systems, including hormonal regulation, metabolism, cardiovascular health, and mental health impacts.
What PMOS Actually Is
PMOS is estimated to affect roughly one in eight women worldwide, or more than 170 million people. Clinically, it is associated with elevated androgen levels, irregular menstrual cycles, insulin resistance, and a range of symptoms that can include acne, excess hair growth, weight changes, and fertility challenges. Experts say the condition is not defined by ovarian cysts alone, a misconception that has contributed to years of delayed diagnosis and inconsistent treatment.
Why Experts Say This Matters
Researchers involved in the change argue that renaming the condition could reshape how it is diagnosed and treated across healthcare systems. By reframing PMOS as a multisystem disease, clinicians may be more likely to screen for related metabolic risks such as type 2 diabetes and cardiovascular disease earlier in life. The change is also expected to influence how patients are referred across specialties, encouraging coordinated care between endocrinology, primary care, reproductive medicine, and mental health services. Public health experts involved in the consensus process say the goal is to reduce stigma and improve recognition of symptoms that were often dismissed or misattributed.
What Changes for Patients Right Now
Despite the new name, diagnostic criteria are expected to remain largely the same in the short term, based on established clinical standards such as irregular ovulation, elevated androgen levels, and ovarian indicators. Health systems are expected to transition gradually, with full adoption of the PMOS terminology projected over the coming years as medical guidelines, education materials, and coding systems are updated.
A Broader Shift in Women’s Health
The renaming is being described by researchers as part of a broader correction in how chronic hormonal disorders are understood. Rather than being treated primarily as reproductive issues, conditions like PMOS are increasingly being recognized as complex metabolic diseases with long-term health consequences that extend well beyond fertility. The Lancet consensus effort behind the change involved global clinicians, researchers, and patient advocacy groups, reflecting a push to align medical terminology more closely with lived patient experience and modern endocrine science.
